Pre-Test The Clinical Potential of Interleukin Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis Pre-Test Which of the following cytokines promotes immune cell differentiation, induction of a Th17 immune response, and the production of inflammatory cytokines involved in psoriasis and psoriatic arthritis pathogenesis? TNF-a IL-17 IL-21 IL-23 Unsure In the Phase 2b FRONTIER 1 clinical trial , a greater proportion of patients with moderate to severe psoriasis who received which of the following achieved PASI 75 (primary endpoint) as well as PASI 90 and PASI 100 compared to placebo at week 16? Guselkumab JNJ-2113 Tildrakizumab Ustekinumab Unsure Which of the following demonstrated significant and durable improvements in symptoms of psoriatic arthritis in patients with PsA who were intolerant to prior TNF-a therapy? Guselkumab Ixekizumab Risankizumab Ustekinumab Unsure How confident are you in your ability to appropriately utilize IL inhibitors in management strategies for psoriasis and psoriatic arthritis? Very Confident Confident Somewhat confident Not very confident Not at all confident
